What's New

Tapering Guidance for Opioids: Existing Best Practices and Evidence Standards

The Action Collaborative on Countering the U.S. Opioid Epidemic hosted a public webinar on July 22nd on best practices and evidence standards for opioid tapering. The webinar featured experts who discussed current guidance for opioid tapering, how this guidance is applied in practice, and the strength of the evidence behind these protocols. Five panelists presented patient case scenarios and discussed pain management challenges through patient and caregiver perspectives, in order to inform best practices and identify evidence gaps. The recorded video and the presentations from the webinar are now available here

Ready to Apply for a 100-Person Waiver Increase? Here's How!

If you have been providing buprenorphine for at least one year, you are now eligible to apply to increase your waiver limit to 100 patients. To apply, please submit an increase request via SAMHSA by completing the Online Notification Form to Increase Patient Limit form.

For more information, please visit SAMHSA’s webpage or contact CSAT's Buprenorphine Information Center at 866-BUP-CSAT (866-287-2728) or send an email to infobuprenorphine@samhsa.hhs.gov.


Welcome to the Oklahoma Medication-Assisted Treatment (MAT) Expansion Project. This project aims to expand access to MAT for persons with opioid use disorder (OUD) by training and supporting rural primary care practices in Oklahoma. Medication-Assisted Treatment is an evidence-based strategy for treating persons with OUD. MAT combines the use of medications with counseling and behavior therapies to provide a whole-patient approach to treatment.

About Oklahoma Rural MAT Expansion

The Problem

Prescription drug overdoses kill nearly two Oklahomans per day. In many rural Oklahoma counties, opioids account for more than half of drug overdose deaths. Oklahoma lacks access to treatment for OUD, particularly in rural areas where there are few primary care providers trained to identify and treat people who are opioid dependent. Many Oklahoma providers are concerned about the devastating effect on their patients and communities. However, many providers also feel overwhelmed at the prospect of offering treatment for OUD in their own practice. Click here for more information about opioid addiction in Oklahoma.

What We Offer

We offer practical, hands-on assistance to you and your office team through training, case-based consultations with addiction specialists, and mentoring from experienced medication-assisted treatment providers. Primary care physicians, nurse practitioners and physician assistants can receive certification and appropriate waivers to treat and manage opioid dependent patients in the office setting. Practices will receive a stipend to facilitate data collection for a planned evaluation of the project. Find out if your practice is eligible to participate.

Who is offering this program?

The American Institutes for Research (AIR) is leading this project in partnership with the state of Oklahoma, the ECHO Institute at the University of New Mexico Health Sciences Center, and the American Society of Addiction Medicine. This project is supported by grant R18HS025067 from the Agency for Healthcare Research and Quality, an agency of the U.S. Department of Health and Human Services. Click here to learn more about partners.

Contact Us

Want to learn more about the project? 
Thank you for your interest in OklahomaMAT! We are currently in the evaluation phase of the project and are no longer enrolling new providers. 

If you'd like to listen to a recording of our informational webinar, entitled "Medication-Assisted Treatment in Rural Oklahoma," please follow this link.

If you have any questions, please contact the AIR team at: OklahomaMAT@air.org or, Phone: 866-236-4285

This project is supported by grant number R18HS025067 from the Agency for Healthcare Research and Quality, an agency of the U.S. Department of Health and Human Services. The content of this website is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality.